Tatva Chintan Pharma Chem Balance Sheet Health
Financial Health criteria checks 6/6
Tatva Chintan Pharma Chem has a total shareholder equity of ₹7.4B and total debt of ₹152.3M, which brings its debt-to-equity ratio to 2.1%. Its total assets and total liabilities are ₹8.1B and ₹694.2M respectively. Tatva Chintan Pharma Chem's EBIT is ₹197.1M making its interest coverage ratio -11.6. It has cash and short-term investments of ₹148.7M.
Key information
2.1%
Debt to equity ratio
₹152.31m
Debt
| Interest coverage ratio | -11.6x |
| Cash | ₹148.73m |
| Equity | ₹7.38b |
| Total liabilities | ₹694.18m |
| Total assets | ₹8.07b |
Recent financial health updates
No updates
Recent updates
Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Price In Tune With Revenues
Sep 26
Tatva Chintan Pharma Chem (NSE:TATVA) Has Affirmed Its Dividend Of ₹2.00
Aug 29Earnings Report: Tatva Chintan Pharma Chem Limited Missed Revenue Estimates By 33%
Jul 27Weak Statutory Earnings May Not Tell The Whole Story For Tatva Chintan Pharma Chem (NSE:TATVA)
May 11Tatva Chintan Pharma Chem Limited's (NSE:TATVA) Share Price Matching Investor Opinion
Apr 04These Analysts Just Made A Notable Downgrade To Their Tatva Chintan Pharma Chem Limited (NSE:TATVA) EPS Forecasts
Jan 26Tatva Chintan Pharma Chem Limited (NSE:TATVA) Analysts Are Reducing Their Forecasts For This Year
May 10Tatva Chintan Pharma Chem Limited Just Missed Revenue By 15%: Here's What Analysts Think Will Happen Next
Jul 28Getting In Cheap On Tatva Chintan Pharma Chem Limited (NSE:TATVA) Is Unlikely
Jun 17Investors Shouldn't Be Too Comfortable With Tatva Chintan Pharma Chem's (NSE:TATVA) Robust Earnings
May 03Are Investors Undervaluing Tatva Chintan Pharma Chem Limited (NSE:TATVA) By 45%?
Dec 06Financial Position Analysis
Short Term Liabilities: TATVA's short term assets (₹2.5B) exceed its short term liabilities (₹678.2M).
Long Term Liabilities: TATVA's short term assets (₹2.5B) exceed its long term liabilities (₹15.9M).
Debt to Equity History and Analysis
Debt Level: TATVA's net debt to equity ratio (0.05%) is considered satisfactory.
Reducing Debt: TATVA's debt to equity ratio has reduced from 85% to 2.1% over the past 5 years.
Debt Coverage: TATVA's debt is well covered by operating cash flow (259.2%).
Interest Coverage: TATVA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 18:04 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Tatva Chintan Pharma Chem Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sanjesh Jain | ICICI Securities Ltd. |
| Anshuman Gupta | Investec Bank plc (UK) |
| Krishanchandra Parwani | JM Financial Institutional Securities Limited |